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Abstract
Background: BRCA1/2 mutation carriers’ choice between risk- reducing salpingo- 
oophorectomy (RRSO) and salpingectomy with delayed oophorectomy is very com-
plex. Aim was to develop a patient decision aid that combines evidence with patient 
preferences to facilitate decision making.
Design: Systematic development of a patient decision aid in an iterative process of 
prototype development, alpha testing by patients and clinicians and revisions using 
International Patient Decision Aid Standards (IPDAS) quality criteria. Information was 
based on the available literature and current guidelines. A multidisciplinary steering 
group supervised the process.
Setting and participants: Pre- menopausal BRCA1/2 mutation carriers choosing be-
tween RRSO and salpingectomy with delayed oophorectomy in Family Cancer Clinics 
in the Netherlands.
Main outcome measures: IPDAS quality criteria, relevance, usability, clarity.
Results: The patient decision aid underwent four rounds of alpha testing and revisions. 
Finally, two paper decision aids were developed: one for BRCA1 and one for BRCA2. 
They both contained a general introduction, three chapters and a step- by- step plan 
containing a personal value clarification worksheet. During alpha testing, risk commu-
nication and information about premature menopause and hormone therapy were the 
most revised items. The patient decision aids fulfil 37 of 43 (86%) IPDAS criteria for 
content and development process.
Discussion and conclusions: Both BRCA1/2 mutation carriers and professionals are 
willing to use or offer the developed patient decision aids for risk- reducing surgery. 
The patient decision aids have been found clear, balanced and comprehensible. Future 
testing among patients facing the decision should point out its effectiveness in im-
proving decision making.
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1  | INTRODUCTION
Women harbouring a germline mutation in the BRCA1 and/or BRCA2 
genes have an increased risk of breast and ovarian cancer.1 The most 
effective way to diminish this ovarian cancer risk is removing fallo-
pian tubes and ovaries during risk- reducing salpingo- oophorectomy 
(RRSO), preferably around the age of 40 years.2,3 However, salpingo- 
oophorectomy at that age results in acute onset of premature meno-
pause with several short- and long- term health consequences.4-6
Therefore, salpingectomy upon completion of childbearing with 
delayed oophorectomy has been proposed as alternative strategy to 
reduce ovarian cancer risk.7-9 This strategy is based on the growing ev-
idence that (serous) ovarian cancer mainly originates from the fallopian 
tube,10-12 and is currently being investigated in a Dutch preference 
trial (NCT02321228).13 However, safety in terms of ovarian cancer 
risk has not been proven yet, which is the main disadvantage of this 
alternative strategy.
Because of different pros and cons of both strategies, the choice 
of trial participants between RRSO and salpingectomy with delayed 
 oophorectomy is complex and highly personal. It is important to educate 
and empower these women in the decision- making process. Previously, 
patient decision aids have been shown to increase knowledge, im-
prove risk perception, lower decisional conflict, reduce proportions of 
people remaining undecided and can improve patient satisfaction.14 
Interestingly, they also increase the number of patients who prefer con-
servative treatment options rather than invasive surgery.14
Currently, no patient decision aid that includes the relatively new 
option of salpingectomy with delayed oophorectomy is available to 
BRCA1/2 mutation carriers, nor in Dutch, nor in English. In the liter-
ature, two randomized controlled trials evaluating patient decision 
aids for women at increased risk of ovarian cancer only included 
RRSO and ovarian screening as options and were developed more 
than 10 years ago.15,16 Patient decision aids about RRSO in BRCA1/2 
mutation carriers do not exist in Dutch. To use English decision aids 
including the RRSO option, as OvDex, which have become available 
online during the last 5 years,17,18 they would need to be extensively 
adjusted because of the additional option of salpingectomy with de-
layed  oophorectomy. Moreover, although OvDex18 can be personal-
ized depending on age, type of mutation and breast cancer history, 
this decision aid is already very long with only two options (surgery 
or no surgery) and only fulfils 4 of 9 International Patient Decision 
Aid Standards (IPDAS)19 criteria to lower the risk of making a biased 
decision. Another decision aid developed by Healthwise17 is short and 
convenient. However, the target population is not limited to BRCA1/2 
mutation carriers, and information about cancer risks is limited and not 
visually presented. Furthermore, these existing decision aids would 
need to be translated from English into Dutch to fit our population.
Therefore, the purpose of this study was to combine evidence 
with patient preferences in a tool that provides decision support 
for BRCA1/2 mutation carriers who participate in the aforemen-
tioned preference trial that compares RRSO with salpingectomy 
and delayed oophorectomy. As a result, the target audience con-
sists of all trial participants: pre- menopausal BRCA1/2 mutation 
carriers who completed childbearing, who are 25- 40 (BRCA1) or 
25- 45 (BRCA2) years old, and who are currently not being treated 
for any malignancy. Three options are discussed in the decision 
aid. The first option is no risk- reducing surgery. Although BRCA1/2 
mutation carriers are rarely reluctant to any kind of risk- reducing 
surgery,20 this option was mentioned in our PtDA to complete 
the overview of options and to place the effects of the other two 
options in perspective. The second option is RRSO between 35- 
40 years old (BRCA1) and 40- 45 years old (BRCA2), as currently 
recommended in national and international guidelines.21,22 The 
third option is risk- reducing salpingectomy upon completion of 
childbearing with delayed oophorectomy between 40- 45 (BRCA1) 
and 45- 50 years old (BRCA2), which has not been proven effective 
yet in terms of improved quality of life or safe in terms of ovarian 
cancer risk. To stick closely to the objective of the preference trial 
and to limit the length of the decision aid, the project group de-
cided to focus on ovarian cancer risk management. Hence, infor-
mation on breast surveillance and risk- reducing mastectomy was 
not included.
2  | MATERIALS AND METHODS
2.1 | Development
Recommendations published by Coulter et al23 guided the develop-
ment process of the patient decision aid (Figure 1). The prototype was 
developed by a project group consisting of a medical doctor, a gynae-
cologic oncologist and an expert in shared decision making and guide-
line implementation, assisted by a patient and professional expert 
panel, and in accordance with the international IPDAS criteria.19 The 
development process was supervised by a steering group, consisting 
of a professor of gynaecologic oncology, professor of hereditary can-
cer and biostatistician. None of the steering group members had any 
conflicts of interests.
2.1.1 | Scope and purpose
Given the complex decision that has to be made within our prefer-
ence trial on RRSO and salpingectomy with delayed oophorectomy 
in BRCA1/2 mutation carriers (NCT02321228),13 the project and 
steering group agreed on the need for a decision support tool for trial 
K E Y W O R D S
ovarian cancer, patient decision aid, premature menopause, salpingectomy, salpingo-
oophorectomy
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participants. Options to be discussed in the decision aid resulted from 
the options within the preference trial.20
2.1.2 | Exploring patients’ decisional needs
Points of consideration in the choice between RRSO and salpingec-
tomy with delayed oophorectomy were extracted from the litera-
ture, searching the Medline database for “BRCA” or equivalents and 
“salpingectomy” or “delayed oophorectomy.” Furthermore, we in-
terviewed 39 BRCA1/2 mutation carriers and 23 of their health- care 
professionals in the process of designing the aforementioned prefer-
ence trial.8 The purpose of these interviews was to explore barriers 
and facilitators for the introduction of salpingectomy with delayed 
oophorectomy as alternative risk- reducing strategy. One year later, a 
random selection of seven of these women attended another session 
to discuss the content of the trial patient information booklet and 
 decision aid.
2.1.3 | Content and format
Based on the identified decisional needs, guidelines and expert opin-
ions, the project group together with the steering group determined 
five domains that are important for decision making in this setting: 
(1) risks and (2) benefits of no surgery, salpingo- oophorectomy and 
salpingectomy with delayed oophorectomy; (3) premature menopause 
and hormone replacement therapy (HRT); (4) strength and availability 
of evidence; and (5) women’s preferences. For the first three domains, 
we collected available literature to compose the content of the deci-
sion aid; the fourth domain was based on appraisal of the evidence 
found. The literature search for domains (1) and (2) is described in 
detail elsewhere.24 The Medline database was searched for the third 
domain using the terms “BRCA” or equivalents and “menopause” or 
equivalents in September 2014. For the fifth domain, the best way to 
clarify individual preferences was also extracted from the literature 
and combined with expert opinions within our project group. To be 
able to hand out and discuss the patient decision aid at the outpatient 
department, the patient decision aid was developed as print book-
let that can be used complimentary to face- to- face counselling. The 
booklet is also a good format to be mailed.
2.2 | Alpha testing and revision
An iterative process of reviewing and revising was followed to de-
velop the version of the patient decision aid that is ready for field 
testing. The first draft was evaluated by a patient communication ex-
pert with experience in increasing readability of booklets, leaflets and 
websites of our institution.
The second draft was sent to a patient expert panel consisting of 
six BRCA1/2 mutation carriers who had one or more consultations at 
our tertiary hospital and had already undergone RRSO. They agreed 
to get invited for any BRCA-related research projects at the time 
they participated in a previous study.8 Although they do not belong 
to the ultimate target population, we invited these women to assess 
the decision aid for two reasons: first, they know the consequences 
of salpingo- oophorectomy from their own experience and second, we 
considered it unethical to offer a preliminary version of the decision aid 
to women who still had to make a choice for either strategy. They were 
asked to fill out a questionnaire on structure, content, layout, length, 
comprehensibility, relevance, credibility and usability of the patient 
decision aid that was (e)mailed to them. The questionnaire contained 
21 questions, of which 13 were open- ended, and was previously used 
in the development of another patient decision aid.25 Additionally, 
the decision aid was discussed during an individual audio- recorded 
telephone interview to let them tell all their thoughts about content, 
wording and presentation to the interviewer.
Based on the received feedback, a third draft was developed 
and alpha- tested. Forty- four BRCA1/2 mutation carriers who had 
undergone pre- menopausal RRSO in our hospital between 2010 
F IGURE  1 Systematic development process of the patient 
decision aid
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and 2015 were sent an invitation letter and informed consent form. 
Names and addresses were retrieved from our institutional opera-
tion room registration system. A reminder was sent after 1 month 
in case of no response. Women who consented to participate were 
sent the decision aid and a short questionnaire with 12 Likert scale 
questions, 12 multiple- choice items and two opportunities for 
suggestions. Questions were about basic demographics, content, 
structure, length, balance, comprehensibility, completeness and 
usefulness. The main difference with the questionnaire in the previ-
ous test round was a lower number of open- ended questions. Again, 
the questionnaire was based on a questionnaire previously used.25 
Participants who did not return their questionnaires were reminded 
three to six times by email and phone. More attempts were found 
to be undesirable and unethical because it could be too disturbing 
and might prejudice the voluntary character of study participation. 
Furthermore, feedback on the decision aid was also requested from 
patient advocates.
As suggested by Coulter et al,23 clinicians were invited to partic-
ipate in alpha testing as well. A revised fourth draft together with an 
adjusted questionnaire was emailed to an expert panel of 14 health- 
care professionals from ten hospitals throughout the country who 
counsel participants about ovarian cancer risk- reducing options in 
the national preference trial. None of them were involved in the ini-
tial development of the decision aid. Although the target audience 
consists of patients and not clinicians, these professionals were 
asked to assess the decision aid for accuracy, balance and presen-
tation of information. They were also asked whether they would be 
willing to hand out this decision aid to their patients. Their sugges-
tions were incorporated in the final version that is ready for field 
testing.
Based on the study design and confirmed by the Medical Ethical 
Committee “CMO Regio Arnhem- Nijmegen,” the Medical Research 
Involving Human Subjects Act (Dutch: WMO) is not applicable to this 
study. Therefore, the study was exempted from being appraised by a 
medical ethical committee.
3  | RESULTS
3.1 | Development
3.1.1 | Patients’ decisional needs
From our qualitative study, we identified the following factors impor-
tant in the decision for salpingo- oophorectomy or salpingectomy with 
delayed oophorectomy: ovarian and breast cancer risks; onset of pre-
mature menopause; level of evidence for the efficacy and safety of 
either strategy; medical history; family history; number of operations.8 
The additional literature search yielded two publications on BRCA1/2 
mutation carriers9 and professionals26 surveyed about salpingectomy 
with delayed oophorectomy. Factors reported to influence the deci-
sion are consequences of premature menopause, HRT, surgical mor-
bidity, potential ovarian damage and lack of data on level of benefit 
and cancer risks.9,26
3.1.2 | Content and format
Search results for domains (1) risks and (2) benefits of no surgery, 
salpingo- oophorectomy and salpingectomy with delayed oophorec-
tomy are described elsewhere.24 Risk estimates based on the literature 
were incorporated into the decision aid. The literature search for the 
third domain concerning premature menopause and HRT yielded 79 
publications. Two relevant articles outlining all aspects of premature 
menopause and HRT in BRCA1/2 mutation carriers were identified 
and used in the decision aid.27,28 Critical appraisal of the level of evi-
dence of selected publications (fourth domain) resulted in how conclu-
sively information was presented. The format of the value clarification 
worksheet (fifth domain) was based on a systematic review29 and the 
experience within our project group.25,30
Analogous to another decision aid,30 ours was subdivided into a 
general introduction, three chapters and a step- by- step plan containing 
a personal value clarification worksheet. Chapter 1 outlines the three 
options in ovarian cancer risk management with the main risks and 
benefits. Chapter 2 contains more specific information on (estimated) 
ovarian and breast cancer risks for the three options. Chapter 3 goes 
into menopause and HRT. The step- by- step plan contained 9 steps 
to guide the user which information should be read, which individual 
values matter most and whether one is well- prepared and confident 
enough to decide. To elicit one’s preferences, eight statements were 
selected based on patients’ decisional needs and had to be scored for 
(dis)agreement on a 6- point Likert scale (3- point Likert scale in the initial 
version). Subsequently, the user is asked to rank the three most import-
ant statements to clarify which values matter most; however, first drafts 
contained a rating instead of a ranking exercise. Finally, implications of 
their stated values for their decision are explicitly shown.
3.2 | Alpha testing and revision
3.2.1 | Alpha testing round 1
The first draft was changed according to the patient communication 
expert’s comments. Wording and sentence structure were adjusted to 
increase readability. Some detailed medical information was removed be-
cause it was thought to be too difficult to understand for the average user. 
Thereupon, 5 of 6 invited BRCA1/2 mutation carriers consented to par-
ticipate in alpha test 1. They filled out a questionnaire and audio- recorded 
telephone interviews were subsequently transcribed by one of the au-
thors (M.H.). Their comments led to several major changes. An image of 
the anatomy of the female internal genitals was added, as was an over-
view of options with their main (dis)advantages. Participants preferred 
icon arrays and pie charts for risk communication, so risk tables, which 
were found confusing, were deleted. Limited alterations were made in 
wording, text order and colour use which resulted in the third draft.
3.2.2 | Alpha testing round 2
Twenty- five of 44 eligible women (57%) signed and returned the in-
formed consent form for participation in the next round that involved 
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the third draft, two declined and 17 responded neither to our let-
ter nor to a reminder. Nineteen of 25 women (76%) who consented 
filled out the semiquantitative questionnaire. Four did not return their 
questionnaires in spite of three to six reminders by phone and email, 
one withdrew her consent and one was physically not able to com-
plete the questionnaire. Baseline characteristics of the 19 participants 
are presented in Table 1. Mean age at RRSO was 42.3 years and 14 
(73.7%) carried a BRCA1 mutation. Twenty per cent were breast can-
cer survivors, and 42% were higher educated.
For chapters 1 and 2 about the three options and (estimated) ovar-
ian and breast cancer risks, the content was judged “good” or “excel-
lent” on a 4- point Likert scale by at least 95% and presentation of 
information was judged “good” or “excellent” by at least 89%. Both 
content and presentation of information in chapter 3 were scored 
“good” or “excellent” in 84% (menopause part) and 74% (HRT part). 
Results of other items surveyed are presented in Table 2. Length and 
the amount of information were assessed “just right” by the majority of 
participants. Including more information about menopause and about 
risks and prognosis of ovarian cancer was suggested. Furthermore, the 
information was mainly judged as balanced, realistic and comprehensi-
ble, and 79% would find it useful in decision making if they would have 
to choose between salpingo- oophorectomy and salpingectomy with 
delayed oophorectomy. The preference elicitation tool of the personal 
worksheet was the most criticized: 32% either wanted to add, remove 
or change some of the statements. No differences were observed 
between women with and without breast cancer history. In general, 
patient reviewers were very positive about the clear language and im-
ages. The decision aid provided readers with easy- to- read information 
to get an overview of all relevant matters. In contrast, suggestions 
for improvement were mainly related to information on menopause 
and HRT, and statements in the preference elicitation tool. A revised 
version of the decision aid was based on all comments of these 19 
patients and four patient advocates. In addition to some textual 
changes, major changes included revision of chapter 3 (menopause 
and HRT), adjustment of statement order in the personal worksheet, 
rephrasing five statements and replacing one statement. Furthermore, 
the initial rating exercise was replaced by the ranking exercise at this 
stage. Moreover, we added more detailed information about ovarian 
cancer prognosis and about the (estimated) risk reduction by the two 
strategies to chapter 1.
3.2.3 | Alpha testing round 3: professionals
Ten of 14 (71%) professionals from eight hospitals then reviewed the 
fourth draft of the decision aid and filled out the questionnaire: eight 
gynaecologic oncologists, one gynaecologist and one medical doctor 
involved in counselling and supportive care of BRCA1/2 mutation car-
riers. For chapters 1 and 2 about the three options and (estimated) 
cancer risks, both content and presentations were judged “good” or 
“excellent” on a 4- point Likert scale by at least 70% of professionals, 
except for the presentation of HRT that was scored “good” or “ex-
cellent” by 60% and “moderate” by the remaining 40%. The major-
ity (70%) found the decision aid too long. Five suggested to develop 
two separate booklets for BRCA1 and BRCA2. Another concern for 
half of the responders was the lack of comprehensibility of the pre-
sented risks. However, the vast majority classified the information 
as balanced and realistic, estimated that it would be a useful tool for 
BRCA1/2 mutation carriers and confirmed to be willing to offer this 
decision aid to their patients additionally to in- person counselling 
(Table 2). One gynaecologic oncologist was not willing to offer this 
decision aid to patients because it was too lengthy.
Besides some textual revisions, three significant changes were 
incorporated into the ultimate version of the decision aid. First, we 
developed separate decision aids for BRCA1 and BRCA2. Second, ex-
amples to estimate ovarian cancer risk were more explicitly described. 
Third, non- hormonal options to alleviate effects of premature meno-
pause were added to chapter 3. Figure 2 shows the personal value 
clarification worksheet (translated from Dutch into English). The final 
version for BRCA1 is added as supporting information (S1, in Dutch, 
could be translated into English upon acceptance).
3.2.4 | IPDAS criteria
Quality of the patient decision aid was tested against the 64 IPDAS 
criteria. As none of the additional criteria were applicable, we checked 
it against the 50 “regular” items and 37 were satisfied. Among the 23 
criteria for “Content,” only criterion 3.9 was not entirely met the fol-
lowing: whether the decision aid allows the user to view probabilities 
based on their own situation (eg age). The decision aid provides one 
example applicable to a certain age. We developed tables with risks 
for various ages24 but those were found to be too complicated for 
this decision aid. However, they are available for health- care provid-
ers and can be discussed during face- to- face contact. Fifteen of 20 
criteria in the “Development Process” were met. We did not use a 
readability score to verify readability (criterion 10.4). In addition, we 
TABLE  1 Baseline characteristics of BRCA1/2 mutation carriers 
who had already undergone risk- reducing salpingo- oophorectomy 
and participated in alpha test round 2
N = 19
Current age (years, mean ± SD) 45.6 ± 3.878 (Range 37-51)
Age at RRSO (years, mean ± SD) 42.3 ± 3.603 (Range 34-48)
Mutation (n)
 BRCA1 14 (73.7%)
 BRCA2 5 (26.3%)
Previous breast cancer (n)
 Yes 4 (21.1%)
 No 15 (78.9%)
Level of education (n)
 Primary/pre- vocational school 2 (10.5%)
 Vocational education 7 (36.9%)
 Pre- college education 2 (10.5%)
 College/university 8 (42.1%)
RRSO, risk- reducing salpingo- oophorectomy.
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have not field- tested the decision aid yet (criteria 1.4- 1.5), although 
we did alpha- test it. Therefore, criteria regarding the results of field 
testing were not satisfied the following: whether it is acceptable (cri-
teria 1.6- 1.7), balanced (criterion 9.3) and can be understood by those 
with limited reading skills (criterion 10.6). Nevertheless, it scored high 
on the first two criteria during alpha testing. The decision aid was not 
evaluated by patients with low health literacy, although it was by one 
dyslectic patient. Lastly, the seven criteria for “Effectiveness” could 
not be assessed because we have not field- tested the final version yet.
4  | DISCUSSION
This paper describes the systematic development process of a paper 
patient decision aid for ovarian cancer risk management in pre- 
menopausal BRCA1/2 mutation carriers, in close collaboration with 
BRCA1/2 mutation carriers and their health- care professionals. The 
decision aid elaborates on the risks and benefits of no surgery, RRSO 
or salpingectomy with delayed oophorectomy. It can be used addi-
tionally to face- to- face consultation. The last version is found to be 
clear, complete, balanced and usable by the vast majority of review-
ers. It fulfils 37 of 43 quality requirements for content and develop-
ment process as formulated in the IPDAS checklist. Patient reviewers 
who underwent risk- reducing surgery before would have liked to use 
the decision aid if they would have to decide now.
The systematic development in a multidisciplinary team and the 
input of patient and professional experts are the main strengths of 
this study. Furthermore, four patient advocates of a national patients’ 
association also reviewed the decision aid. The last strength is that 
we present the user with the implications of their expressed values in 
the personal worksheet, supposedly leading to better outcomes when 
using value clarification methods.29
The most important limitation in the development of this patient 
decision aid is the lack of (univocal) evidence for some items. First, 
salpingectomy with delayed oophorectomy has not been clinically 
investigated yet, so its effect on ovarian cancer risk is unknown. 
Second, health consequences of premature menopause in this par-
ticular population has not been entirely unravelled and the same 
applies to the effect of HRT. However, there are no convincing 
TABLE  2 Alpha testing among BRCA1/2 mutation carriers and 
their health- care providers
Draft 3 
BRCA mutation 
carriers (n = 19)
Draft 4 
Health- care 
providers (n = 10)
Length of PtDA, n (%)
Too long 1 (5%) 7 (70%)
Too short 2 (11%) 0
Just right 16 (84% 2 (20%)
Missing 0 1 (10%)
Amount of information, n (%)
Too much 1 (5%) 1 (10%)
Too little 6 (32%) 1 (10%)
Just right 12 (63%) 3 (30%)
Missing 0 5 (50%)
Information balanced?, n (%)
Yes 15 (79%) 8 (80%)
Slanted towards RRSO 3 (16%) 0
Slanted towards RRS/
RRO
1 (5%) 2 (20%)
PtDA is comprehensible, n (%)
In general 17 (89%) N/A
Risk communication
Yes 17 (89%) 4 (40%)
No 2 (11%) 4 (40%)
Missing 0 2 (20%)
Consequences of RRSO, n (%)
Realistic 16 (84%) 9 (90%)
Underestimated 3 (16%) 1 (10%)
Consequences of RRS/RRO, n (%)
Realistic 13 (68%) 10 (100%)
Underestimated 5 (27%) 0
Overestimated 1 (5%) 0
Useful in decision making, n (%)
Yes 15 (79%) 8 (80%)
No 3 (16%) 0
Missing 1 (5%) 2 (20%)
Sufficient information to decide, n (%)
Yes 16 (84%) 8 (80%)
No 3 (16%) 1 (10%)
Missing 0 1 (10%)
Personal worksheet statements, n (%)
Are well chosen 12 (63%) 6 (60%)
At least one needs to be 
removed
5 (27%) 1 (10%)
At least one needs to be 
added
1 (5%) 0
Missing 1 (5%) 3 (30%)
(Continues)
Draft 3 
BRCA mutation 
carriers (n = 19)
Draft 4 
Health- care 
providers (n = 10)
Willing to offer PtDA to patients, n (%)
Yes N/A 8 (80%)
No, not this PtDA N/A 1 (10%)
No, no PtDA at all N/A 0
Missing N/A 1 (10%)
PtDA, patient decision aid; RRSO, risk- reducing salpingo- oophorectomy; 
RRS/RRO, risk- reducing salpingectomy with delayed risk- reducing 
 oophorectomy; N/A, not applicable.
TABLE  2  (Continued)
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arguments to expect differences between BRCA1/2 mutation car-
riers and the general population regarding effects of premature 
menopause. Furthermore, existing evidence only provides relative 
risks, which are very hard to be interpreted. For instance, a two- to 
four- fold increase in the risk of cardiovascular disease is very hard to 
translate into absolute risks without knowing the background risk, 
which depends on lifestyle, personal and family medical history et-
cetera. Furthermore, we did not alpha- test the decision aid in the 
actual target population because lack of experience with premature 
menopause and because of ethical reasons. For the first reason, 
we neither invited women who underwent only a salpingectomy 
before, although that could have revealed additional issues to take 
into account in decision making. Women with low literacy skills were 
under- represented in both alpha tests: a common problem in this 
kind of research that we were not able to resolve.14 In addition, we 
were not able to check our patient decision aid against a standard 
readability score because no widely used and validated readability 
score is available for Dutch texts. Readability scores for English do 
not apply to Dutch.
Two randomized controlled trials evaluating patient decision aids 
for women at increased risk of ovarian cancer only included RRSO 
and ovarian screening as options.15,16 One also contained information 
on breast cancer risk management options besides those for ovarian 
cancer.15 All together, they found that women who used the decision 
aid felt better informed and were more satisfied with the amount 
and quality of received information compared with women who re-
ceived usual care. Furthermore, users’ risk estimates for ovarian can-
cer were more accurate and they chose risk- reducing surgery more 
often. However, no statistically significant differences were found for 
well- being and decision- related outcomes, possibly because of lack 
F IGURE  2 Personal value clarification 
worksheet of final draft (translated from 
Dutch into English)
Questionnaire accompanying Step 4:
Indicate the extent to which you agree or disagree with each of the following statements by 
putting a cross in the relevant box. There are no right or wrong answers; this is about your
thoughts and your ideas. You can use the lines at the end to add any arguments that you 
consider important, but which are missing from the questionnaire.
STATEMENT AGREE DISAGREE
A I dread operations
B I am unwilling to choose a treatment that has not been 
proved to be effective
C I think that I have an extra high risk of ovarian cancer
D I think that my chances of developing cardiovascular 
disease are lower than average 
E I will do anything to avoid developing cancer (again) 
F I’m not at all worried about the menopause 
G I don’t have a problem with hormone therapy (either 
medically or personally)
H I don’t see any reason to do anything to lower my risk of 
ovarian cancer earlier than the recommended age (35-40 
years)
I _______________________________________________
_______________________________________________
J _______________________________________________
_______________________________________________
Indicate below which three statements weigh most heavily for you by noting down the letters 
in order of importance. 
1. ___
2. ___
3. ___
If you mainly ‘agree’ with these three statements, removal of the fallopian tubes and ovaries 
is the best option for you.
If you mainly ‘disagree’ with these three statements, initial removal of the fallopian tubes and 
removal of the ovaries at a later date is the best option for you.
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of power. Tiller et al16 developed their decision aid for women with 
a family history of breast and/or ovarian cancer or Lynch syndrome. 
Besides ovarian screening and RRSO, information about watchful 
waiting and chemoprevention was included. Women who used the 
decision aid reported higher acceptability and the received informa-
tion as more sufficient and helpful in decision making compared with 
women receiving a general educational pamphlet. Greater knowledge 
and lower decisional conflict were found 2 weeks after the interven-
tion but did not last after 6 months. Use of the decision aid did not 
affect psychological outcomes.16 Besides, several decision aids on 
management options of breast cancer risk in BRCA1/2 mutation carri-
ers have been developed and tested.31-34 Women who used these de-
cision aids also reported less decisional conflict, reduced uncertainty 
and cancer- specific distress, increased knowledge and more satisfac-
tion with their decision.31-34
In conclusion, our systematically developed patient decision aid for 
pre- menopausal BRCA1/2 mutation carriers participating in a Dutch 
clinical preference trial (NCT02321228) appears to be acceptable 
and usable according to both patients and professionals. However, 
whether its use really lowers decisional conflict, increases patient 
satisfaction and results in informed decisions that are congruent with 
personal values has to be studied yet. Moreover, the rapidly growing 
body of evidence for this particular population will require regular up-
dates of the content of the patient decision aid.
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